Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Sclerosis (SSc) Clear all
Not yet recruiting Phase 3 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 12:54 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 12:54 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Interventions
TAK-007, Chemotherapy Agents
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 12:54 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 22, 2026, 12:54 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
IgPro10, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
rapamycin, methotrexate
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced May 22, 2026, 12:54 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced May 22, 2026, 12:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Covina, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced May 22, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions
HZN-825
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Calcinosis Cutis
Interventions
Sodium Thiosulfate (STS), Sodium Thiosulfate Injection
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced May 22, 2026, 12:54 AM EDT
Enrolling by invitation Phase 1 Interventional
View directory record Official record
Conditions
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Redwood City, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 12:54 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Scleroderma
Interventions
Privigen
Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced May 22, 2026, 12:54 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RENEW
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced May 22, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced May 22, 2026, 12:54 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Scleroderma, Ssc
Interventions
Occupational therapy treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced May 22, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced May 22, 2026, 12:54 AM EDT